Jim Tananbaum is the celebrated CEO and founder of Foresite Capital Management. The company specializes in identifying talented healthcare leaders who help it grow towards higher profitability by supplying networks capital, and information. Jim architected the company as a healthcare-committed private equity firm in 2011.
Before founding Foresite Capital, Jim was a co-founder of two biopharmaceutical companies including GelTex Pharmaceuticals and Theravance, Inc. Moreover, he was a former CEO of the latter. Jim also co-founded two healthcare investment practices including Prospect Partners II and III and Sierra Ventures. He has also been involved in several investments such as Healthon NASDAQ: WBMD and Amerigroup NASDAQ: AMGP.
Jim is a former student of Yale University where he acquired his B.S in Electrical Engineering. Jim graduated with an MBA from the prestigious Harvard Business School. He also obtained his M.S from the renowned Massachusetts Institute of Technology.
How Foresite Capital Come Emerged
In an interview with IdeaMensch, Jim cited that the idea behind the establishment of Foresite Capital came from his experience as a healthcare entrepreneur and investment strategist for more than 25 years. He mentioned that the Foresite meant understanding and harnessing the future of the healthcare industry. Currently, the company has invested in 77 healthcare companies in diagnostic, biopharmaceutical, and medical services.
Why Jim Tananbaum is Successful
Jim cited that he brought ideas to life by engaging talented and persistent leaders in healthcare. He mentioned that he was excited with the trend of science behind healthcare innovation. This is because science defined him and inspired him through the way entrepreneurs solved healthcare needs. Jim confirmed that he was a successful entrepreneur because of his love for learning more to find the best solutions in science.
Jim has been the Managing Director and CEO since the establishment of Foresite Capital Management in 2011. As the chief architect of the investment strategy of the company, he has been a great contributor in many Foresite companies.
Jim Tananbaum is currently a member of the Board of Directors of NovaMed EyeCare and Patient Care, Inc. He is also the Founding affiliate of the Harvard/MIT Health Science and Technology Advisory Group. Jim is the vice chairman of the Pathology Advisory Group and Harvard Medical School Cell Biology.
Posted by TrinaS on .